Mahumud Rashidul Alam

Dr Rashidul Alam Mahumud is a health economist and high-achieving early-career researcher (ECR) at NHMRC Clinical Trial Centre (CTC), The University of Sydney, with extensive experience and analytical skills in health economics, economic evaluation, clinical epidemiology, health outcome measures, biostatistics, and public health research in oncology, and chronic disease management. Dr Mahumud currently works as a Research Fellow in Health Economics to assess the clinical and economic value of various cancer and chronic disease treatments. He recently completed a PhD in health economics (July 2020) on the cancer burden in Australia at USQ, Australia. Before joining the CTC, Dr Mahumud undertook postdoctoral training (Health Economics and Public Health data scientist) at the Western Sydney University, Nov 2019-Nov 2020. Dr Mahumud served as a health economist researcher at icddr,b, Dhaka, Bangladesh (from 2012 to 2017) to implement, design and evaluate the effectiveness of several interventions and programs and perform health economic analyses. In total, Dr Mahumud has been awarded approximately $14 million AUD. Dr Mahumud has produced 110 total career publications, including 97 peer-reviewed articles in the last 5 years (80% of his publications in Q1 ranked journals), 2 reviews, and 3 book chapters with over 1035 citations (well above average for ECRs <2 year FTE post-PhD, 3-year postdoc) and has an H-index of 26. Dr Mahumud’s expertise has been internationally recognised serving as Public Health and Health Economics editor for two prestigious Q1-ranked journals (BMC Public Health- Associate Editor) and PLoS ONE (Academic Editor), providing peer-review in public health and health economics, and extending his research network of public health professionals and health economist reviewers. Dr Mahumud was nominated as a Distinguished Talent under the Global Talent Independent Program, Australian Government, June 2020. He has received several publication excellence Awards. Dr Mahumud is an expert on assessing the clinical and economic value of various cancer and chronic disease treatments and collaborative clinical studies and hence is well-positioned to lead economic analysis in the clinical trials.